NaNotics LLC (Mill Valley, California) has announced that it will work with the Mayo Clinic to develop a cancer treatment known as NaNots that works by depleting targeted pathogenic molecules from the blood. The NaNot would target a soluble form of programmed death-ligand 1 (PD-L1), a tumor-generated immune inhibitor, while ignoring membrane forms of PD-L1.
“Our team has been studying sPD-L1 for several years,” said Dr. Sean Park, an oncologist at Mayo Clinic, in a statement. “We believe it’s a key driver of immune evasion for many tumor types.”
Park said the ability to home in on soluble PD-L1 is “potentially significant.”
“We’re excited to collaborate with NaNotics and test NaNots against sPD-L1 in humans for the first time,” he added.
NaNotics hopes to file an investigational new drug (IND) application with the FDA to begin human clinical trials within…